and Drug Administration said on its website. The recall was initiated on Jan. 27 but made public by the FDA this week. The latest recall is for Lupin`s branded drug Suprax, the brand name for cefixime—an antibiotic used to treat bacterial infections of the ear and upper respiratory tract.
7.13 PM Apr 15th
Now Orchid is in a low margin business. The recent US fDA approval is only a RENEWAL not much of a great thing. Comparing Wock with Orchid is not a wise comparison. I dont intend to discourage you and tell that it is not a turnaround story. But, too early; there r no such signals of recovery. Let
1.34 PM Apr 15th
Considering company`s strong R&D pipeline ,I believe company can regain the reduced business in another few years .Recently U. S. health regulator Food & Drug Administration (FDA) inspected its Irungattukottai, Chennai-based oral formulations facility and approved it without any observations
12.50 PM Apr 15th
at Rs. 650 it is hopelessly undervalued. Now there are two scenarios 1. The FDA woes continue. Even in such a situation I think Rs. 700 is a good valuation even if they maintain their current cash flows. 2. If they settle their FDA woes soon then when they get back to normal valuation and they start
4.03 PM Apr 14th
Says Sarabjit Kour Nangra, vice-president for pharmaceutical research, Angel Broking: "Nothing substantial has come out of the development. The FDA needs to approve this and, till then, I don`t read much into this news development. However, the markets are expecting the FDA to take steps that could
11.07 PM Apr 13th
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.